Results 151 to 160 of about 154,177 (308)

Hyaluronic Acid-PEG-PLGA Nanoparticles Encapsulating Myricetin Attenuate NMDA-Induced Retinal Ganglion Cell Injury Associated with Microglia-Related Neuroinflammatory Responses. [PDF]

Int J Nanomedicine
Yang X, Xu J, Long L, Wang Q, Ji S, Tang S, Ma JH.   +6 more
europepmc   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

Characterization of a monkey model with experimental retinal damage induced by N-methyl-D-aspartate

Disease Models & Mechanisms
Guo Liu, Longxiang Huang, Junkai Tan, Yun Wang, Chunlin Lan, Yaxi Chen, Yukai Mao, Xizhen Wang, Ning Fan, Yihua Zhu, Xianjun Zhu, Xuyang Liu   +11 more
doaj   +1 more source

Structure-based molecular modeling of a novel S-Remiketamine scaffold and derived arylcyclohexanone analogues: NMDA receptor dynamics, MM-GBSA ranking, and CES1-Oriented structural compatibility. [PDF]

Front Chem
Alkhatip AAAMM, Raza U, Farag E, Hamza MK, Hosny H, Sallam A, Farag AMG, Wagih M, Naguib A, Abdulmegid AM, Algameel H, Bahr MH.   +11 more
europepmc   +1 more source

Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan, Nazli Tunali, R. Andrew Chambers   +2 more
wiley   +1 more source

Diversity of glutamate receptors in glial cells of the mouse optic nerve. [PDF]

Front Cell Neurosci
Kompier NF, Semtner M, Walter S, Steinhäuser C, Nolte C, Kettenmann H.   +5 more
europepmc   +1 more source

Emollient Formulations and Skin Barrier Practices in the Context of Eczema and Food Allergy Prevention

Allergy, EarlyView.
ABSTRACT The skin is far from a passive shield; it functions as a dynamic “living barrier” whose structural and immunological integrity is paramount in preventing atopic dermatitis (AD) and the subsequent progression of the atopic march toward food allergy (FA).
Klaudia Ryczaj, Donald Y. M. Leung, Carina Venter, Barbara Sozańska, Helen A. Brough   +4 more
wiley   +1 more source

Spatial covariance of mGluR5 density and structural degeneration in behavioral variant frontotemporal degeneration. [PDF]

Imaging Neurosci (Camb)
Matyi MA, Pecsok MK, Olm CA, Radhakrishnan H, Dratch L, Van Deerlin VM, Rhodes E, Phillips JS, Cook PA, Gee JC, Irwin DJ, McMillan CT, Roalf D, Massimo L.   +13 more
europepmc   +1 more source

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

Brain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero‐Murillo, Djordje Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría   +7 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source